TITLE

Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells

AUTHOR(S)
Wai Feng Lim; Tomoko Inoue-Yokoo; Keai Sinn Tan; Lai, Mei I.; Daisuke Sugiyama
PUB. DATE
July 2013
SOURCE
Stem Cell Research & Therapy;2013, Vol. 4 Issue 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pluripotent stem cells, both embryonic stem cells and induced pluripotent stem cells, are undifferentiated cells that can self-renew and potentially differentiate into all hematopoietic lineages, such as hematopoietic stem cells (HSCs), hematopoietic progenitor cells and mature hematopoietic cells in the presence of a suitable culture system. Establishment of pluripotent stem cells provides a comprehensive model to study early hematopoietic development and has emerged as a powerful research tool to explore regenerative medicine. Nowadays, HSC transplantation and hematopoietic cell transfusion have successfully cured some patients, especially in malignant hematological diseases. Owing to a shortage of donors and a limited number of the cells, hematopoietic cell induction from pluripotent stem cells has been regarded as an alternative source of HSCs and mature hematopoietic cells for intended therapeutic purposes. Pluripotent stem cells are therefore extensively utilized to facilitate better understanding in hematopoietic development by recapitulating embryonic development in vivo, in which efficient strategies can be easily designed and deployed for the generation of hematopoietic lineages in vitro. We hereby review the current progress of hematopoietic cell induction from embryonic stem/induced pluripotent stem cells.
ACCESSION #
89687570

 

Related Articles

  • Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: case studies. Ratcliffe, Elizabeth; Glen, Katie E.; Naing, May Win; Williams, David J. // British Medical Bulletin;Dec2013, Vol. 108 Issue 1, p73 

    Background Apart from haematopoietic stem cell transplantation for haematological disorders many stem cell-based therapies are experimental. However, with only 12 years between human embryonic stem cell isolation and the first clinical trial, development of stem cell products for regenerative...

  • F4/80+ Host Macrophages Are a Barrier to Murine Embryonic Stem Cell-Derived Hematopoietic Progenitor Engraftment . Thompson, Heather L.; van Rooijen, Nico; McLelland, Bryce T.; Manilay, Jennifer O. // Journal of Immunology Research;10/30/2016, p2414906 

    Understanding how embryonic stem cells and their derivatives interact with the adult host immune system is critical to developing their therapeutic potential. Murine embryonic stem cell-derived hematopoietic progenitors (ESHPs) were generated via coculture with the bone marrow stromal cell line,...

  • Strategies for enrichment and selection of stem cell-derived tissue precursors. Bernstein, Harold S.; Hyun, William C. // Stem Cell Research & Therapy;2012, Vol. 3 Issue 3, p1 

    Human embryonic stem cells have the capacity for self-renewal and pluripotency and thus are a primary candidate for tissue engineering and regenerative therapies. These cells also provide an opportunity to study the development of human tissues ex vivo. To date, numerous human embryonic stem...

  • Emerging concepts for the in vitro derivation of murine haematopoietic stem and progenitor cells. Garcia-Alegria, Eva; Menegatti, Sara; Batta, Kiran; Cuvertino, Sara; Florkowska, Magdalena; Kouskoff, Valerie // FEBS Letters;Nov2016, Vol. 590 Issue 22, p4116 

    Well into the second decade of the 21st century, the field of regenerative medicine is bursting with hopes and promises to heal young and old. The bespoken generation of cells is thought to offer unprecedented cures for a vast range of diseases. Haematological disorders have already benefited...

  • Modeling hematopoietic transplantation with ES cells  // Molecular Therapy;May2004 Supplement 1, Vol. 9, p353 

    An abstract of the article "Modeling Hematopoietic Transplantation with ES Cells," by George Q. Daley is presented.

  • SSEA-4+ CD34- Cells in the Adult Human Heart Show the Molecular Characteristics of a Novel Cardiomyocyte Progenitor Population. Sandstedt, Joakim; Jonsson, Marianne; Vukusic, Kristina; Dellgren, Göran; Lindahl, anders; Jeppsson, anders; asp, Julia // Cells Tissues Organs;Dec2014, Vol. 199 Issue 2/3, p103 

    Stage-specific embryonic antigen (SSEA) expression is used to describe the differentiation state of an embryonic stem cell (ESC). In human ESCs, SSEA-3 and SSEA-4 are highly expressed in undifferentiated cells and downregulated upon differentiation. SSEA-4 has also been described as a marker for...

  • Integration-deficient lentivectors: an effective strategy to purify and differentiate human embryonic stem cell-derived hepatic progenitors. Guanghua Yang; Si-Tayeb, Karim; Corbineau, Sébastien; Vernet, Rémi; Gayon, Régis; Dianat, Noushin; Martinet, Clémence; Clay, Denis; Goulinet-Mainot, Sylvie; Tachdjian, Gérard; Burks, Deborah; Vallier, Ludovic; Bouillé, Pascale; Dubart-Kupperschmitt, Anne; Weber, Anne // BMC Biology;2013, Vol. 11 Issue 1, p1 

    Background: Human pluripotent stem cells (hPSCs) hold great promise for applications in regenerative medicine. However, the safety of cell therapy using differentiated hPSC derivatives must be improved through methods that will permit the transplantation of homogenous populations of a specific...

  • Functional Cardiomyocytes Derived from Isl1 Cardiac Progenitors via Bmp4 Stimulation. Cagavi, Esra; Bartulos, Oscar; Suh, Carol Y.; Sun, Baonan; Yue, Zhichao; Jiang, Zhengxin; Yue, Lixia; Qyang, Yibing // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    As heart failure due to myocardial infarction remains a leading cause of morbidity worldwide, cell-based cardiac regenerative therapy using cardiac progenitor cells (CPCs) could provide a potential treatment for the repair of injured myocardium. As adult CPCs may have limitations regarding...

  • Human Bone Marrow Mesenchymal Stem Cells: A Systematic Reappraisal Via the Genostem Experience. Charbord, Pierre; Livne, Erella; Gross, Gerhard; Häupl, Thomas; Neves, Nuno M.; Marie, Pierre; Bianco, Paolo; Jorgensen, Christian // Stem Cell Reviews & Reports;Mar2011, Vol. 7 Issue 1, p32 

    Genostem (acronym for "Adult mesenchymal stem cells engineering for connective tissue disorders. From the bench to the bed side") has been an European consortium of 30 teams working together on human bone marrow Mesenchymal Stem Cell (MSC) biological properties and repair capacity. Part of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics